CreativeOne Wealth LLC Grows Holdings in Amgen Inc. (NASDAQ:AMGN)

CreativeOne Wealth LLC increased its position in Amgen Inc. (NASDAQ:AMGN) by 29.4% during the third quarter, HoldingsChannel.com reports. The firm owned 10,392 shares of the medical research company’s stock after acquiring an additional 2,364 shares during the quarter. CreativeOne Wealth LLC’s holdings in Amgen were worth $3,348,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of AMGN. Kennedy Capital Management LLC bought a new position in Amgen in the 1st quarter worth about $3,240,000. LRI Investments LLC purchased a new stake in shares of Amgen during the 1st quarter valued at about $152,000. Redwood Grove Capital LLC boosted its holdings in shares of Amgen by 17.2% during the 1st quarter. Redwood Grove Capital LLC now owns 47,687 shares of the medical research company’s stock valued at $13,558,000 after acquiring an additional 7,000 shares during the last quarter. Cetera Investment Advisers boosted its holdings in shares of Amgen by 268.9% during the 1st quarter. Cetera Investment Advisers now owns 233,379 shares of the medical research company’s stock valued at $66,355,000 after acquiring an additional 170,108 shares during the last quarter. Finally, Cetera Advisors LLC boosted its holdings in shares of Amgen by 151.3% during the 1st quarter. Cetera Advisors LLC now owns 70,984 shares of the medical research company’s stock valued at $20,182,000 after acquiring an additional 42,739 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Trading Up 0.0 %

Shares of AMGN opened at $280.07 on Thursday. The company’s fifty day moving average is $313.58 and its 200 day moving average is $317.57. Amgen Inc. has a fifty-two week low of $257.80 and a fifty-two week high of $346.85. The stock has a market capitalization of $150.55 billion, a PE ratio of 35.86, a P/E/G ratio of 2.62 and a beta of 0.60. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, topping the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The company had revenue of $8.50 billion for the quarter, compared to analysts’ expectations of $8.50 billion. During the same quarter in the previous year, the business posted $4.96 earnings per share. Amgen’s quarterly revenue was up 23.2% on a year-over-year basis. Sell-side analysts expect that Amgen Inc. will post 19.52 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be paid a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a yield of 3.21%. The ex-dividend date is Monday, November 18th. Amgen’s payout ratio is 115.24%.

Analyst Ratings Changes

A number of analysts have recently issued reports on AMGN shares. Oppenheimer reaffirmed an “outperform” rating and set a $380.00 price target on shares of Amgen in a report on Wednesday, August 7th. Citigroup dropped their price target on shares of Amgen from $335.00 to $310.00 in a report on Wednesday. Wells Fargo & Company downgraded shares of Amgen from an “overweight” rating to an “equal weight” rating and raised their price target for the company from $320.00 to $335.00 in a report on Wednesday, August 7th. Sanford C. Bernstein assumed coverage on shares of Amgen in a report on Thursday, October 17th. They set an “outperform” rating and a $380.00 price target on the stock. Finally, Royal Bank of Canada dropped their price objective on shares of Amgen from $360.00 to $330.00 and set an “outperform” rating on the stock in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $323.05.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.